News & Updates

Show Multimedia Only

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

08 Feb 2021 by

Adding oxaliplatin to adjuvant fluoropyrimidine improves overall survival (OS) and disease-free survival (DFS) in patients with microsatellite instability (MSI) stage III colon cancer, a pooled analysis of 12 randomized clinical trials has shown.

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

08 Feb 2021

Paediatric-onset IBD linked to cancer risk

07 Feb 2021

Patients with paediatric-onset inflammatory bowel disease (IBD) suffer from a greater risk of developing malignancies, reports a new meta-analysis.

Paediatric-onset IBD linked to cancer risk

07 Feb 2021

Reduced TKI dose on par with standard dose for NSCLC

06 Feb 2021

Initiating tyrosine kinase inhibitor (TKI) therapy at a reduced dose appears to result in progression-free survival (PFS) and 15-month survival outcomes comparable to TKI therapy at the Food and Drug Administration (FDA) standard dose, reports a study.

Reduced TKI dose on par with standard dose for NSCLC

06 Feb 2021

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients

06 Feb 2021

A polygenic risk score (PRS) helps identify organ transplant recipients (OTRs) who are at high risk of developing keratinocyte cancers (KCs), which in turn could improve screening and preventive strategies, a new study has found.

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients

06 Feb 2021

Smoking effect on colorectal neoplasia risk may vary by IBD type

05 Feb 2021 by

The impact of cigarette smoke exposure on the risk of colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD) may differ according to IBD type, suggested results of a single-centre study presented at the recent Crohn’s and Colitis Congress 2021.

Smoking effect on colorectal neoplasia risk may vary by IBD type

05 Feb 2021

Spicy food boasts antigastrointestinal cancer potential

05 Feb 2021 by

Frequent consumption of spicy food appears to protect against the risk of gastrointestinal cancers, especially oesophageal cancer, and this association is pronounced among individuals who do not smoke and drink regularly, according to a study.

Spicy food boasts antigastrointestinal cancer potential

05 Feb 2021

IPF patients at higher risk of cancer incidence

05 Feb 2021

A recent study has found a higher risk of cancer incidence in patients with idiopathic pulmonary fibrosis (IPF) than in those without IPF. Thus, healthcare providers should be made aware of such risk when treating IPF patients.

IPF patients at higher risk of cancer incidence

05 Feb 2021

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021 by

Bayer reveals major transformation in its pharmaceutical business with the use of breakthrough innovations aimed at helping patients with difficult-to-treat conditions.

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

03 Feb 2021 by

Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

03 Feb 2021

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients

03 Feb 2021 by

The addition of obinutuzumab or rituximab to chemotherapy* (O-CT or R-CT, respectively) similarly led to HRQoL** improvements in patients with previously untreated advanced follicular lymphoma (FL), according to the phase III GALLIUM study.

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients

03 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

Paediatric-onset IBD linked to cancer risk

Paediatric-onset IBD linked to cancer risk

Reduced TKI dose on par with standard dose for NSCLC

Reduced TKI dose on par with standard dose for NSCLC

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients

Smoking effect on colorectal neoplasia risk may vary by IBD type

Smoking effect on colorectal neoplasia risk may vary by IBD type

Spicy food boasts antigastrointestinal cancer potential

Spicy food boasts antigastrointestinal cancer potential

IPF patients at higher risk of cancer incidence

IPF patients at higher risk of cancer incidence

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients